Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models
B Higgins, K Kolinsky, M Smith, G Beck… - Anti-cancer …, 2004 - journals.lww.com
Our objective was the preclinical assessment of the pharmacokinetics, monotherapy and
combined antitumor activity of the epidermal growth factor receptor (HER1/EGFR) tyrosine
kinase inhibitor erlotinib in athymic nude mice bearing non-small cell lung cancer (NSCLC)
xenograft models. Immunohistochemistry determined the HER1/EGFR status of the NSCLC
tumor models. Pharmacokinetic studies assessed plasma drug concentrations of erlotinib in
tumor-and non-tumor-bearing athymic nude mice. These were followed by maximum …
combined antitumor activity of the epidermal growth factor receptor (HER1/EGFR) tyrosine
kinase inhibitor erlotinib in athymic nude mice bearing non-small cell lung cancer (NSCLC)
xenograft models. Immunohistochemistry determined the HER1/EGFR status of the NSCLC
tumor models. Pharmacokinetic studies assessed plasma drug concentrations of erlotinib in
tumor-and non-tumor-bearing athymic nude mice. These were followed by maximum …